메디톡스

086900KOSDAQ기초 의약물질 제조업

57.3 / 100

Reference Date: 2026-06-10

Financial Score20.0 / 40

News Sentiment19.3 / 25

Momentum6.0 / 20

Disclosure12.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit metrics are weak. Plunged 23.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Medytox specializes in the research, development, manufacturing, and sales of biopharmaceuticals using botulinum toxin type A, with flagship products such as Meditoxin® and Innotox®. In 2024, its key pharmaceutical products accounted for approximately 84% of consolidated revenue, and the company has expanded exports to over 30 countries.

Number of Employees

753people

Average Salary

64.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

33.36Industry Average 27.713.0Point

Higher than industry avg (caution)

PBR

1.27Industry Average 1.745.5Point

Lower than industry avg (good)

ROE

3.39Industry Average -6.033.5Point

Well below industry avg

Debt Ratio

4.99Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.8% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.5% (2-year basis)

ROE Trend

1.0 / 4

Avg ROE 3.0% (improving, 3yr)

Detailed News Sentiment

14 totalPositive 11Neutral 2Negative 1Average Sentiment Score 77.1

Positive
메디톡스, 50억 규모 자사주 취득 결정
메디톡스의 자사주 취득 결정으로 주가 안정과 주주 가치 제고 기대.
Positive
메디톡스, 그리스기업에 '뉴라덤' 공급…유럽 7개국 진출
메디톡스의 뉴라덤 브랜드가 그리스를 포함한 유럽 7개국에 진출함으로써 글로벌 시장 확장에 긍정적 영향을 미칠 것으로 예상됩니다.
Positive
메디톡스 화장품 브랜드 ‘뉴라덤’, 유럽 독점 공급 계약 체결
메디톡스의 화장품 브랜드 뉴라덤이 그리스 AMG사와의 독점 공급 계약 체결로 인해 성장 기대감이 높아짐.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 79,100Won52-week high 177,90052-week low 79,100

1-month return0.0Point

1m -23.28% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

3 totalPositive 1Neutral 2Negative 0

Positive주요사항보고서(자기주식취득결정)2026-06-09
Neutral분기보고서 (2026.03)2026-05-15
Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-05-12